Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
Form 4 overview: UnitedHealth Group Inc. (UNH) reported one insider transaction by Patrick H. Conway, Chief Executive Officer of Optum. On 24 June 2025, Conway acquired 73.058 shares of common stock at a stated price of $0.00. The shares represent dividend equivalents that accrue on previously granted restricted stock units (RSUs); they will vest or be forfeited under the same conditions as the underlying RSUs.
Following the credit, Conway’s total beneficial ownership increased to 10,471.511 shares, held in direct form. No derivative securities were reported in this filing, and there were no dispositions or sales.
Key points for investors:
- The transaction is non-open-market and mechanically linked to existing RSUs, signalling neither an active purchase nor a sale decision.
- The share increase is immaterial—about 0.7% of Conway’s reported holdings and negligible relative to UnitedHealth’s ~930 million shares outstanding.
- No Rule 10b5-1 trading plan was indicated, and there are no signs of strategic shifts, financing activities, or performance commentary in the filing.
Overall, the Form 4 reflects routine compensation-related activity with neutral implications for UnitedHealth shareholders.
Form 4 filing overview for UnitedHealth Group Inc. (UNH)
Chief Accounting Officer Thomas E. Roos reported a small automatic acquisition of company stock on 24 June 2025. The filing discloses the crediting of 25.252 dividend-equivalent shares tied to previously granted restricted stock units (RSUs). These shares were received at $0 cost, consistent with the dividend-equivalent feature of the RSUs. Following the transaction, Roos’ direct beneficial ownership increased to 29,524.318 common shares.
No derivative securities were acquired or disposed of, and there were no open-market purchases or sales. The transaction code “A” confirms it was an acquisition rather than a sale, and the explanation section clarifies that the shares will forfeit if the underlying RSUs fail to vest.
Investor takeaway: The filing reflects routine dividend-equivalent accretion and signals continued alignment of the senior officer’s compensation with shareholder returns, but the volume (<1% of the insider’s holdings) is immaterial to UNH’s share float and is unlikely to influence market sentiment.
Transaction details: On 24 June 2025 UnitedHealth Group Inc. (UNH) director Michele J. Hooper received 266 shares of UNH common stock, as disclosed in a Form 4 filed with the SEC on 26 June 2025. The shares were credited as dividend equivalents on previously vested deferred stock units (DSUs); accordingly, no cash consideration was paid (transaction price reported as $0) and no open-market trade occurred.
Post-transaction ownership: Following the award, Ms. Hooper's direct ownership increased to 40,306 shares. No derivative securities were acquired or disposed, and there were no sales. The filing indicates direct ownership (box "D") and does not reference a Rule 10b5-1 trading plan.
Investor context: A 266-share increment represents less than 1% of Ms. Hooper's holdings and is immaterial relative to UnitedHealth's roughly 930 million outstanding shares. Such dividend-equivalent accruals are routine for deferred equity awards and generally signal neither bullish nor bearish sentiment. The filing does, however, reaffirm the director's continuing equity alignment with shareholders.
Insider activity: On 24 Jun 2025, UnitedHealth Group (UNH) director and former CEO Stephen J. Hemsley reported the credit of 55 common shares at $0 cost, reflecting dividend-equivalent units paid on previously vested deferred stock units. These shares were immediately vested and subject to the same terms as the underlying units. Following the credit, Hemsley’s direct holdings rose to roughly 374,407.942 shares, alongside 347.29 shares held through a 401(k) plan and 735,115 shares held via family trusts. No derivative securities were exercised, and the filing does not reference a Rule 10b5-1 trading plan. The adjustment is routine, immaterial relative to Hemsley’s more than 1.1 million-share beneficial stake, and is unlikely to influence market perception or valuation.
FAQ
What is the current stock price of Unitedhealth Gp (UNH)?
What is the market cap of Unitedhealth Gp (UNH)?
